{
    "organizations": [],
    "uuid": "f28c13bf435c67cf062a5449bf73b61c36169b38",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-announces-d/brief-aralez-pharmaceuticals-announces-discontinuation-of-u-s-commercial-operations-with-reductions-in-operating-expenses-idUSFWN1SF0PH",
    "ord_in_thread": 0,
    "title": "BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of U.S. Commercial Operations, With Reductions In Operating Expenses",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Aralez Pharmaceuticals Inc:\n* ARALEZ ANNOUNCES NEW STRATEGIC DIRECTION * ARALEZ PHARMACEUTICALS INC - DISCONTINUATION OF U.S. COMMERCIAL OPERATIONS, WITH SIGNIFICANT REDUCTIONS IN OPERATING EXPENSES\n* ARALEZ PHARMACEUTICALS INC - FOCUS ON CANADIAN OPERATIONS, SUPPORTED BY TOPROL-XL FRANCHISE REVENUES AND VIMOVO ROYALTIES\n* ARALEZ PHARMACEUTICALS INC - CONCLUDED THAT MOMENTUM FROM ZONTIVITY ALONE IS INSUFFICIENT TO SUSTAIN U.S. COMMERCIAL INFRASTRUCTURE\n* ARALEZ PHARMACEUTICALS INC - ACTIVELY EXPLORING STRATEGIC ALTERNATIVES FOR BUSINESS\n* ARALEZ PHARMACEUTICALS INC - ARALEZ CANADA WILL FOCUS ON DRIVING ORGANIC GROWTH IN CANADA WITH BLEXTEN AND CAMBIA\n* ARALEZ PHARMACEUTICALS INC - ARALEZ EXPECTS CASH OPERATING EXPENSES WILL BE REDUCED TO ABOUT $25 MILLION ON AN ANNUALIZED BASIS\n* ARALEZ PHARMACEUTICALS INC - STRATEGIC ALTERNATIVES INCLUDE ACTIVE DISCUSSIONS TO DIVEST U.S. RIGHTS TO YOSPRALA, FIBRICOR AND BEZALIP SR\n* ARALEZ PHARMACEUTICALS INC - COMPANY CAUTIONS THAT IT HAS VERY RECENTLY EXPERIENCED INCREASED GENERIC COMPETITION WITH RESPECT TO TOPROL-XL FRANCHISE\n* ARALEZ PHARMACEUTICALS INC - STRATEGIC ALTERNTIVES ALSO INCLUDE BROADER STRATEGIC AND REFINANCING ALTERNATIVES FOR ITS BUSINESS\n* ARALEZ PHARMACEUTICALS INC - EVALUATING MARKET DYNAMICS, EXPLORING OPPORTUNITIES TO MITIGATE RISK INVOLVED WITH TOPROL-XL FRANCHISE COMPETITION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-08T19:10:00.000+03:00",
    "crawled": "2018-05-09T12:15:42.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aralez",
        "pharmaceutical",
        "inc",
        "aralez",
        "announces",
        "new",
        "strategic",
        "direction",
        "aralez",
        "pharmaceutical",
        "inc",
        "discontinuation",
        "commercial",
        "operation",
        "significant",
        "reduction",
        "operating",
        "expense",
        "aralez",
        "pharmaceutical",
        "inc",
        "focus",
        "canadian",
        "operation",
        "supported",
        "franchise",
        "revenue",
        "vimovo",
        "royalty",
        "aralez",
        "pharmaceutical",
        "inc",
        "concluded",
        "momentum",
        "zontivity",
        "alone",
        "insufficient",
        "sustain",
        "commercial",
        "infrastructure",
        "aralez",
        "pharmaceutical",
        "inc",
        "actively",
        "exploring",
        "strategic",
        "alternative",
        "business",
        "aralez",
        "pharmaceutical",
        "inc",
        "aralez",
        "canada",
        "focus",
        "driving",
        "organic",
        "growth",
        "canada",
        "blexten",
        "cambium",
        "aralez",
        "pharmaceutical",
        "inc",
        "aralez",
        "expects",
        "cash",
        "operating",
        "expense",
        "reduced",
        "million",
        "annualized",
        "basis",
        "aralez",
        "pharmaceutical",
        "inc",
        "strategic",
        "alternative",
        "include",
        "active",
        "discussion",
        "divest",
        "right",
        "yosprala",
        "fibricor",
        "bezalip",
        "sr",
        "aralez",
        "pharmaceutical",
        "inc",
        "company",
        "caution",
        "recently",
        "experienced",
        "increased",
        "generic",
        "competition",
        "respect",
        "franchise",
        "aralez",
        "pharmaceutical",
        "inc",
        "strategic",
        "alterntives",
        "also",
        "include",
        "broader",
        "strategic",
        "refinancing",
        "alternative",
        "business",
        "aralez",
        "pharmaceutical",
        "inc",
        "evaluating",
        "market",
        "dynamic",
        "exploring",
        "opportunity",
        "mitigate",
        "risk",
        "involved",
        "franchise",
        "competition",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}